Last mentioned: Feb 24, 2026
Payer Agreement Shift
New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
Q4 Milestone
Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
GLP-1 Strategic Acquisition
Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
Rezdiffra Full-Year Launch
Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.
Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.